messaggio

clik on the image and visit the new site

New site clik on the image

"In silico"


From Wikipedia
If the target host* of a phage therapy treatment is not an animal the term "biocontrol" (as in phage-mediated biocontrol of bacteria) is usually employed, rather than "phage therapy".

In silico
From:"Genomics,Proteomics and Clinical Bacteriology",N.Woodford and Alan P.Johnson

Phrase that emphasizes the fact that many molecular biologists spend increasing amounts of their time in front of a computer screen, generating hypotheses that can subsequently be tested and (hopefully) confirmed in the laboratory.


Phage Therapy is influenced by:

Phage therapy is influenced by:

Country : the epidemiological situation is different from country to country in terms of circulating bacteria and bacteriophages. Example: lytic phages from Italy may be no active on the same bacteria (genus and species) isolated from another country and vice versa.
Temporariness
Mutation rate
Phenotypical delay
Phage cocktail

My point of view

Sunday 2 May 2010

Mycobacterium smegmatis: Mpr protein










The problem is to identify the phage receptor.
If Mpr protein of M.smegmatis arrests the growth of D29 and L5 mycobacterium phages then this protein may be involved with the phage receptors and also it must a transmembrane protein.

Mpr protein (multicopy phage resistance) as the capacity to react with Phage proteins and to arrest the Phage cycle.

Elevation of Mpr is thought to cause resistance to D29 infection by inhibiting transport of phage DNA across the cell wall.
Over expression of this gene also confers resistance to L5 and partial resistance to TM4 but
does not effect infection by Bxb1 or I3 (Barsom and Hatfull 1996).

1-copy the protein sequence in Tmap program ( predict and plot transmembrane segments in protein sequences, Jemboss software)
2-safe the result

3- copy the protein sequence in MPEx ( Membrane Protein Explorer,open source)
4-safe the result

5- copy the protein sequence in TMRPres2D software
6-safe the image